on March 1, 2004
Published online before print March 1, 2004, doi: 10.1161/01.CIR.0000121426.43044.2B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© American Heart Association, Inc.
Basic Science Reports |
Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy
From the Sections of Cardiology and Cardiovascular Sciences, Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, Tex., Guest Editor for this article was Christine E. Seidman, MD, Harvard Medical School, Boston, Mass.
Reprint requests to A.J. Marian, MD, Baylor College of Medicine, Section of Cardiology, One Baylor Plaza, 519D, Houston, TX 77030. E-mail amarian{at}bcm.tmc.edu
Received December 30, 2003; revision received January 21, 2004; accepted January 29, 2004.
Background— Human hypertrophic cardiomyopathy (HCM), the most common cause of sudden cardiac death in the young, is characterized by cardiac hypertrophy, myocyte disarray, and interstitial fibrosis. The genetic basis of HCM is largely known; however, the molecular mediators of cardiac phenotypes are unknown.
Methods and Results— We show myocardial aldosterone and aldosterone synthase mRNA levels were elevated by 4- to 6-fold in humans with HCM, whereas cAMP levels were normal. Aldosterone provoked expression of hypertrophic markers (NPPA, NPPB, and ACTA1) in rat cardiac myocytes by phosphorylation of protein kinase D (PKD) and expression of collagens (COL1A1, COL1A2, and COL3A1) and transforming growth factor-ß1 in rat cardiac fibroblasts by upregulation of phosphoinositide 3-kinase (PI3K)-p100
. Inhibition of PKD and PI3K-p110 abrogated the hypertrophic and profibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolactone. Spironolactone reversed interstitial fibrosis, attenuated myocyte disarray by 50%, and improved diastolic function in the cardiac troponin T (cTnT)-Q92 transgenic mouse model of human HCM. Myocyte disarray was associated with increased levels of phosphorylated ß-catenin (serine 38) and reduced ß-catenin–N-cadherin complexing in the heart of cTnT-Q92 mice. Concordantly, distribution of N-cadherin, predominantly localized to cell membrane in normal myocardium, was diffuse in disarrayed myocardium. Spironolactone restored ß-catenin–N-cadherin complexing and cellular distribution of N-cadherin and reduced myocyte disarray in 2 independent randomized studies.
Conclusions— The results implicate aldosterone as a major link between sarcomeric mutations and cardiac phenotype in HCM and, if confirmed in additional models, signal the need for clinical studies to determine the potential beneficial effects of MR blockade in human HCM.
Key Words: cardiomyopathy • myocytes • hypertrophy
This article has been cited by other articles:
 |
|
 |
|
  M. S. Maron, I. Olivotto, B. J. Maron, S. K. Prasad, F. Cecchi, J. E. Udelson, and P. G. Camici The case for myocardial ischemia in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., August 25, 2009; 54(9): 866 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bos, J. A. Towbin, and M. J. Ackerman Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 201 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lombardi, J. Dong, G. Rodriguez, A. Bell, T. K. Leung, R. J. Schwartz, J. T. Willerson, R. Brugada, and A. J. Marian Genetic Fate Mapping Identifies Second Heart Field Progenitor Cells As a Source of Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy Circ. Res., May 8, 2009; 104(9): 1076 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis Eur. Heart J., January 9, 2009; (2009) ehn538v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Elliott and P Spirito Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice Heart, October 1, 2008; 94(10): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schulz-Menger, H. Abdel-Aty, A. Rudolph, T. Elgeti, D. Messroghli, W. Utz, P. Boye, S. Bohl, A. Busjahn, B. Hamm, et al. Gender-specific differences in left ventricular remodelling and fibrosis in hypertrophic cardiomyopathy: Insights from cardiovascular magnetic resonance Eur J Heart Fail, September 1, 2008; 10(9): 850 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Diez Effects of Aldosterone on the Heart: Beyond Systemic Hemodynamics? Hypertension, September 1, 2008; 52(3): 462 - 464. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lombardi, A. Bell, V. Senthil, J. Sidhu, M. Noseda, R. Roberts, and A. J. Marian Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies Cardiovasc Res, July 1, 2008; 79(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. McEneaney, B. J. Harvey, and W. Thomas Aldosterone Regulates Rapid Trafficking of Epithelial Sodium Channel Subunits in Renal Cortical Collecting Duct Cells via Protein Kinase D Activation Mol. Endocrinol., April 1, 2008; 22(4): 881 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grossmann, R. Freudinger, S. Mildenberger, B. Husse, and M. Gekle EF Domains Are Sufficient for Nongenomic Mineralocorticoid Receptor Actions J. Biol. Chem., March 14, 2008; 283(11): 7109 - 7116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Avkiran, A. J. Rowland, F. Cuello, and R. S. Haworth Protein Kinase D in the Cardiovascular System: Emerging Roles in Health and Disease Circ. Res., February 1, 2008; 102(2): 157 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-L. Ambroisine, J. Favre, P. Oliviero, C. Rodriguez, J. Gao, C. Thuillez, J.-L. Samuel, V. Richard, and C. Delcayre Aldosterone-Induced Coronary Dysfunction in Transgenic Mice Involves the Calcium-Activated Potassium (BKCa) Channels of Vascular Smooth Muscle Cells Circulation, November 20, 2007; 116(21): 2435 - 2443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schroen, J. J. Leenders, A. van Erk, A. T. Bertrand, M. van Loon, R. E. van Leeuwen, N. Kubben, R. F. Duisters, M. W. Schellings, B. J. Janssen, et al. Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy J. Exp. Med., May 14, 2007; 204(5): 1227 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. McKinsey Derepression of pathological cardiac genes by members of the CaM kinase superfamily Cardiovasc Res, March 1, 2007; 73(4): 667 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Wenxia Chai, Y. M Hoedemaekers, R. H. van Schaik, M. van Fessem, I. M Garrelds, J. J Saris, D. Dooijes, F. J ten Cate, M. M. Kofflard, and A. J. Danser Cardiac aldosterone in subjects with hypertrophic cardiomyopathy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 225 - 230. [Abstract] [PDF]
|
|
|
|
|
|
C. Y. Ho and C. E. Seidman A Contemporary Approach to Hypertrophic Cardiomyopathy Circulation, June 20, 2006; 113(24): e858 - e862. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Marian, V. Senthil, S. N. Chen, and R. Lombardi Antifibrotic Effects of Antioxidant N-Acetylcysteine in a Mouse Model of Human Hypertrophic Cardiomyopathy Mutation J. Am. Coll. Cardiol., February 21, 2006; 47(4): 827 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Fuller and M. J. Young Mechanisms of Mineralocorticoid Action Hypertension, December 1, 2005; 46(6): 1227 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Paterson, J. R. Seckl, and J. J. Mullins Genetic manipulation of 11{beta}-hydroxysteroid dehydrogenases in mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R642 - R652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Binder, M. A. Fifer, M. E. King, and J. R. Stone Case 26-2005 - A 48-Year-Old Man with Sudden Loss of Consciousness while Jogging N. Engl. J. Med., August 25, 2005; 353(8): 824 - 832. [Full Text] [PDF]
|
|
|
|
|
|
V. Senthil, S. N. Chen, N. Tsybouleva, T. Halder, S. F. Nagueh, J. T. Willerson, R. Roberts, and A.J. Marian Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy Circ. Res., August 5, 2005; 97(3): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J C Moon, J Mogensen, P M Elliott, G C Smith, A G Elkington, S K Prasad, D J Pennell, and W J McKenna Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I Heart, August 1, 2005; 91(8): 1036 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fiebeler, J. Nussberger, E. Shagdarsuren, S. Rong, G. Hilfenhaus, N. Al-Saadi, R. Dechend, M. Wellner, S. Meiners, C. Maser-Gluth, et al. Aldosterone Synthase Inhibitor Ameliorates Angiotensin II-Induced Organ Damage Circulation, June 14, 2005; 111(23): 3087 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rozengurt, O. Rey, and R. T. Waldron Protein Kinase D Signaling J. Biol. Chem., April 8, 2005; 280(14): 13205 - 13208. [Full Text] [PDF]
|
|
|
|
|
|
F. Dequiedt, J. Van Lint, E. Lecomte, V. Van Duppen, T. Seufferlein, J. R. Vandenheede, R. Wattiez, and R. Kettmann Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis J. Exp. Med., March 7, 2005; 201(5): 793 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lutucuta, N. Tsybouleva, M. Ishiyama, G. DeFreitas, L. Wei, B. Carabello, and A.J. Marian Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2221 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Vega, B. C. Harrison, E. Meadows, C. R. Roberts, P. J. Papst, E. N. Olson, and T. A. McKinsey Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5 Mol. Cell. Biol., October 1, 2004; 24(19): 8374 - 8385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garnier, J. K. Bendall, S. Fuchs, B. Escoubet, F. Rochais, J. Hoerter, J. Nehme, M.-L. Ambroisine, N. De Angelis, G. Morineau, et al. Cardiac Specific Increase in Aldosterone Production Induces Coronary Dysfunction in Aldosterone Synthase-Transgenic Mice Circulation, September 28, 2004; 110(13): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|